Evommune (EVMN) Change in Acquisitions & Divestments (2024 - 2026)

Evommune (EVMN) has reported Change in Acquisitions & Divestments for 3 consecutive years, with $23.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments rose 74.07% year-over-year to $23.5 million; the TTM figure through Mar 2026 stood at $86.1 million (changed N/A YoY), while the FY2025 annual figure was $84.1 million, down 2.61% from the prior year.
• Change in Acquisitions & Divestments retreated to $23.5 million in Q1 2026 per EVMN's latest filing, from $37.6 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $37.6 million in Q4 2025 and bottomed at $11.5 million in Q4 2024.
• Historically, Change in Acquisitions & Divestments has averaged $21.5 million across 3 years, with a median of $18.5 million in 2025.
• Annual changes were most pronounced in 2025 — Change in Acquisitions & Divestments jumped 226.96% — and 2026, when it surged 74.07%.
• Evommune's Change in Acquisitions & Divestments stood at $11.5 million in 2024, then surged by 226.96% to $37.6 million in 2025, then plunged by 37.5% to $23.5 million in 2026.
• Business Quant data shows EVMN's Change in Acquisitions & Divestments at $23.5 million in Q1 2026, $37.6 million in Q4 2025, and $13.5 million in Q1 2025.